Related Experiment Video
Updated: Jul 18, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Paxlovid-Induced Tacrolimus Toxicity in the Treatment of COVID-19: A Case Report
Stephanie Michael1, Rachel Heilbronner2, Christopher M Lloyd1
1Emergency Medicine, OhioHealth Doctors Hospital, Columbus, USA.
Abstract:
PaxlovidTM (nirmaltrelvir/ritonavir) received emergency use authorization from the Food and Drug Administration (FDA) in December 2021 to treat coronavirus disease 2019 (COVID-19). Given the actions of Paxlovid on cytochrome P450-3A4 (CYP3A4) enzymes, it is imperative to check for potential drug-drug interactions before prescribing. We describe a case in which the common emergency department presentation of generalized weakness was found to be caused by interactions between Paxlovid and a patient's home medications resulting in tacrolimus toxicity.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Drug Toxicity: Risk factors
Drug Toxicity: Allergic Reactions
Drug toxicity: Idiosyncratic Reactions
Pericarditis III: Medical Management

